Literature DB >> 15613116

Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.

Massimo Breccia, Gianna Maria D'Elia, Mariella D'Andrea, Roberto Latagliata, Giuliana Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15613116     DOI： 10.1111/j.1600-0609.2004.00347.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  9 in total

Review 1.  Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.

Authors:  Chandra K Ala; Allan L Klein; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

2.  Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.

Authors:  Julien Mahé; Emilie Patras de Campaigno; Anne-Laure Chené; Jean-Louis Montastruc; Fabien Despas; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2018-08-05       Impact factor: 4.335

3.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

4.  Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.

Authors:  Biren Saraiya; Rashmi Chugh; Vassiliki Karantza; Janice Mehnert; Rebecca A Moss; Nelli Savkina; Mark N Stein; Laurence H Baker; Thomas Chenevert; Elizabeth A Poplin
Journal:  Invest New Drugs       Date:  2010-08-10       Impact factor: 3.850

5.  Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.

Authors:  David A Dorr; Rachel Burdon; Dennis P West; Jennifer Lagman; Christina Georgopoulos; Steven M Belknap; June M McKoy; Benjamin Djulbegovic; Beatrice J Edwards; Sigmund A Weitzman; Simone Boyle; Martin S Tallman; Moshe Talpaz; Oliver Sartor; Charles L Bennett
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

Review 6.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

Review 7.  Serous fluids and hematolymphoid disorders.

Authors:  Ali Gabali
Journal:  Cytojournal       Date:  2022-03-19       Impact factor: 2.345

Review 8.  Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.

Authors:  Kevin Kelly; Ronan Swords; Devalingam Mahalingam; Swaminathan Padmanabhan; Francis J Giles
Journal:  Target Oncol       Date:  2009-04-21       Impact factor: 4.493

Review 9.  Repurposing of Kinase Inhibitors for Treatment of COVID-19.

Authors:  Ellen Weisberg; Alexander Parent; Priscilla L Yang; Martin Sattler; Qingsong Liu; Qingwang Liu; Jinhua Wang; Chengcheng Meng; Sara J Buhrlage; Nathanael Gray; James D Griffin
Journal:  Pharm Res       Date:  2020-08-10       Impact factor: 4.580
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.